C.Q. Pharmaceutical Holding (000950.SZ) issued a profit warning, with an estimated net profit of 290 million to 390 million yuan, a year-on-year decrease of 40.45% to 55.72%.

C.Q. Pharmaceutical Holding (000950.SZ) disclosed its performance forecast for the year 2024, with the company expecting a net profit attributable to shareholders of the listed company of 290 million to 390 million yuan, a year-on-year decrease of 40.45% to 55.72%; the net profit after deducting non-recurring gains and losses is expected to be 240 million to 320 million yuan, a year-on-year decrease of 45.07% to 58.80%. The main reasons for the decrease in performance during the reporting period are: the expansion of the scope of drug and medical device quantity procurement, with national centralized procurement, provincial-level centralized procurement, and alliance centralized procurement all being fully implemented, further prompting adjustments in drug and medical device prices and affecting the company's profitability; and an increase in credit period for customer accounts receivable, resulting in impairment losses due to the expected credit loss rate, leading to a decrease in profits.